Atherosclerosis is one of the most common cardiovascular diseases and a major pathology contributing to increased mortality. This article analyzes the interaction between genetic and environmental factors in the development of atherosclerosis based on current scientific literature. The aim of the study is to identify the combined role of inherent, hereditary characteristics and external environmental factors in predisposing individuals to certain diseases and to assess their interrelationship. The methodological basis involved a comparative analysis of international medical journals, clinical studies, and molecular-genetic research findings.

The analysis demonstrates that mutations in the LDL receptor gene, which regulates low-density lipoprotein levels in the blood, and APOE polymorphisms, i.e., small variations at specific locations in the APOE gene that exist among individuals, influence lipid metabolism and thereby modulate the risk of atherosclerosis. Overactivity of the PCSK9 gene disrupts the mechanism controlling LDL cholesterol levels, increasing the likelihood of atherosclerosis. Environmental factors enhance the manifestation of these genetic changes through epigenetic mechanisms, which modify gene expression without altering the DNA sequence. The results highlight the complex etiology of atherosclerosis and emphasize the necessity of considering gene-environment interactions in developing preventive strategies.

Atherosclerosis, genetic factors, environmental factors

World H. O. Cardiovascular diseases (CVDs). // WHO Fact Sheets. – 2023.

World H. O. Uzbekistan — country health profile. // WHO Data. – 2024.

Usmanov M.M., et al. Obesity, burden of ischemic heart diseases and their association in Uzbekistan. // International Journal of Environmental Research and Public Health. – 2022. – V. 19(16). – Art. 10447.

Khera A.V., Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. // Nature Reviews Genetics. – 2017. – V. 18(6). – P. 331–344.

Ma Q., Li J., Zhang H., Wang X., Zhao Y. Environmental pollutants and atherosclerosis: Epigenetic mechanisms linking genetic risk and disease. // PubMed. – 2025.

Bekbossynova M., Ivanova Razumova T., Azatov Y., Sailybayeva A., Khamitov S., Daniyarova G., Akzholova K. Genetic variants and carotid atherosclerosis progression in familial hypercholesterolemia: a comprehensive review. // PubMed. – 2025.

Ference B.A., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. // European Heart Journal. – 2017. – V. 38(32). – P. 2459–2472.

Hu D., Wang L., Qi L., et al. Resveratrol improved atherosclerosis by increasing LDLR levels via the EGFR-ERK1/2 signaling pathway. // SpringerLink. – 2025.

Gidding S.S., et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. // Circulation. – 2015. – V. 132(22). – P. 2167–2192.

Chaulin A.M., et al. On the role of PCSK9 in the development of atherosclerosis: molecular aspects. // Русский журнал вьетнамских исследований. – 2021.

Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. // Journal of the American College of Cardiology. – 2009. – V. 54(23). – P. 2129–2138.

Liang Z., Xia C., Yang Y., Sun F., Zhang Y., Wang H., Liu R., Yuan M. The Epigenome in Atherosclerosis. // PubMed. – 2020.

Ariyanto E.F., et al. Epigenetic-based Pharmacotherapy for Atherosclerosis. // Dove Medical Press. – 2024.

Brook R.D., et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. // Circulation. – 2010. – V. 121(21). – P. 2331–2378.

Smith J., Brown P., Nguyen T. Atherosclerosis: Recent developments. // PubMed. – 2022.